Duchenne Muscular Dystrophy (DMD) affects millions globally, necessitating a robust market for effective treatments. The current DMD treatment landscape is characterized by an focus on symptom management and supportive care. However, recent advances in gene therapy and drugs are paving the way for potential curative options. Research are actively